Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, now recruiting.
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) is a phase 3 interventional study registered as NCT06170788 by Merck Sharp & Dohme LLC, with 614 participants planned, started 2023-12-15 and due to reach its primary completion in 2028-01-25. Interventions recorded: Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures. Conditions listed: Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Merck & Co. (MSD), Small-cell lung cancer, Pembrolizumab.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares PD-L1-high non-small-cell lung cancer without a driver mutation, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Merck & Co. (MSD), Antibody-drug conjugate (ADC).